NCT04176497View on ClinicalTrials.gov

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

February 7, 2024

Study Completion Date

February 7, 2028

Conditions
Prostate Cancer
Interventions
DRUG

68Ga-HBED-CC-PSMA

Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.

Trial Locations (1)

27599

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER